Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study
- Conditions
- Non ST Segment Elevation Acute Coronary SyndromeChronic Coronary Syndrome
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Meditrix Corp
- Target Recruit Count
- 307
- Registration Number
- NCT05117866
- Locations
- 🇮🇪
CORRIB Research Centre for Advanced Imaging and Core laboratoryNational University of Ireland, Galway, Galway, Ireland
🇯🇵Fujita Health University, Toyoake, Aichi, Japan
🇯🇵Fujita Health University, Okazaki Medical Centre, Okazaki, Aichi, Japan
Replication of the ISAR-REACT 5 Antiplatelet Trial in Healthcare Claims Data
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 28389
- Registration Number
- NCT05086081
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
- Conditions
- Acute Coronary SyndromeAtrial Fibrillation
- Interventions
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 2334
- Registration Number
- NCT04981041
- Locations
- 🇩🇪
Deutsches Herzzentrum München, Munich, Bayern, Germany
🇩🇪Kerckhoff-Klinik GmbH, Herzzentrum, Bad Nauheim, Germany
🇩🇪Universitätsklinikum Freiburg, Universitäts-Herzzentrum Klinik für Kardiologie & Angiologie, Campus Bad Krozingen, Bad Krozingen, Germany
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy
- Conditions
- Non ST Segment Elevation Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2023-03-06
- Target Recruit Count
- 75
- Registration Number
- NCT04766437
- Locations
- 🇳🇱
Amsterdam UMC, location AMC, Amsterdam, Netherlands
Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 492
- Registration Number
- NCT04734353
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Gyeongsang National University Hospita, Jinju, Gyeongsangnam-do, Korea, Republic of
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
- Conditions
- Coronary Artery DiseaseAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 359
- Registration Number
- NCT04668144
- Locations
- 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States
Prasugrel in Severe COVID-19 Pneumonia
- Conditions
- COVID19Thrombosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-06-26
- Target Recruit Count
- 128
- Registration Number
- NCT04445623
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 43864
- Registration Number
- NCT04237922
- Locations
- 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 90
- Registration Number
- NCT04006288
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
- Target Recruit Count
- 204
- Registration Number
- NCT03672097
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳Cheng Hsin General Hospital, Taipei, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.